Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Jaguar Health Inc
(NQ:
JAGX
)
0.1800
+0.0100 (+5.88%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Jaguar Health Inc
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
15
16
Next >
Jaguar Health Subsidiary Napo Pharmaceuticals Announces Activation by FDA of Investigational New Drug (IND) Application for NP-300, a Novel Drug Candidate for the Symptomatic Relief and Treatment of Diarrhea from Cholera and Other Pathogens
September 29, 2022
Via
ACCESSWIRE
Jaguar Health to Present at Lytham Partners Fall 2022 Investor Conference on September 28th and at Ladenburg Thalmann 2022 Healthcare Conference on September 29th
September 22, 2022
Via
ACCESSWIRE
Why NeuroBo Pharmaceuticals Is Trading Higher By Around 55%; Here Are 25 Stocks Moving Premarket
September 15, 2022
Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) rose 54.6% to $26.07 in pre-market trading after the company entered into an exclusive license agreement with Dong-A.
Via
Benzinga
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
August 30, 2022
Via
Benzinga
Jaguar Health Provides Company Updates and Reports 2022 Second Quarter Financials
August 22, 2022
Via
ACCESSWIRE
Jaguar Health to Host Investor Webcast Monday, August 22nd at 8:30 AM Eastern Time Regarding Q2 2022 Financials & Corporate Updates
August 17, 2022
Via
ACCESSWIRE
Jaguar Health Seeks FDA Nod For Cholera Candidate Study
August 30, 2022
Jaguar Health (NASDAQ: JAGX) has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for its subsidiary Napo's NP-300 drug product candidate for the...
Via
Benzinga
Jaguar Health Announces Submission of Investigational New Drug (IND) Application to FDA for Drug Candidate for the Symptomatic Relief of Diarrhea from Cholera
August 30, 2022
Via
ACCESSWIRE
Jaguar Health Secures Additional Capital Through Sale of Royalty Rights Related to Future Crofelemer and Lechlemer Revenue Stream
August 25, 2022
Via
ACCESSWIRE
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
August 23, 2022
Via
Benzinga
Looking Into Jaguar Health's Return On Capital Employed
August 23, 2022
According to Benzinga Pro data, during Q2, Jaguar Health (NASDAQ:JAGX) posted sales of $2.92 million. Earnings were up 48.3%, but Jaguar Health still reported an overall loss of $9.39 million.
Via
Benzinga
Jaguar Health Announces that Orphan Drug Designation Application Submitted to the FDA for Crofelemer for a Severe Congenital Diarrheal Disorder (CDD) Has Been Accepted for Review
August 23, 2022
Via
ACCESSWIRE
Jaguar Health Announces Issuance of U.S. Patent 11,389,424, a Methods and Compositions Patent for Treating Chemotherapy-Induced Diarrhea
August 09, 2022
Via
ACCESSWIRE
Short Volatility Alert: Jaguar Health, Inc.
July 05, 2022
On Friday, shares of Jaguar Health, Inc. (NASDAQ: JAGX) experienced volatile short activity. After the activity, the stock price went up +4.83% to $0.3082. The overall sentiment for JAGX has been...
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
August 22, 2022
Gainers ABVC BioPharma (NASDAQ:ABVC) shares increased by 12.8% to $0.97 during Monday's after-market session. The company's market cap stands at $31.6 million.
Via
Benzinga
Earnings Scheduled For August 22, 2022
August 22, 2022
Companies Reporting Before The Bell • Jaguar Health (NASDAQ:JAGX) is estimated to report quarterly loss at $0.22 per share on revenue of $3.10 million.
Via
Benzinga
Jaguar Health's Earnings: A Preview
August 19, 2022
Jaguar Health (NASDAQ:JAGX) is set to give its latest quarterly earnings report on Monday, 2022-08-22. Here's what investors need to know before the announcement. Analysts estimate that Jaguar Health...
Via
Benzinga
Jaguar Health Receives Additional 180-day Grace Period to Regain Compliance with Nasdaq's Bid Price Rule
August 19, 2022
Via
ACCESSWIRE
Gallup Survey Estimates Nearly 30 Million U.S. Dog Owners Have Experienced Canine Cancer, with Many Saying it Negatively Impacted Their Own Quality of Life
August 10, 2022
Via
ACCESSWIRE
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 05, 2022
Via
ACCESSWIRE
Stocks That Hit 52-Week Lows On Thursday
July 28, 2022
On Thursday, 108 companies set new 52-week lows.
Via
Benzinga
Why This Biotechnology Surged More Than 60%; Here Are 67 Biggest Movers From Yesterday
July 27, 2022
Gainers Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) shares surged 94.3% to close at $1.69 on Tuesday after the company filed a request for the withdrawal of the Registration Statement on Form S-1.
Via
Benzinga
Jaguar Health Appoints Senior Healthcare and Investment Executive Dr. Anula Jayasuriya to Board of Directors and Forms Business Development Advisory Committee to Assess Opportunities for Alliances, Mergers, and Acquisitions
July 05, 2022
Greg Divis departs from Jaguar's Board of Directors; Experienced business development executive Rachel Zolot Schwartz chairs new committee
From
Jaguar Health, Inc.
Via
AccessWire
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 01, 2022
SAN FRANCISCO, CA / ACCESSWIRE / July 1, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective June 27, 2022, the Company granted 60,000 restricted stock...
From
Jaguar Health, Inc.
Via
AccessWire
Jaguar Health Enters Exclusive Crofelemer License and Commercialization Agreement with SynWorld Technologies for Canalevia for Treatment of Diarrhea in Dogs in China
June 29, 2022
License fees of $5.0 million, and up to $5.0 million in unregistered equity infusion, over next 24 months
From
Jaguar Health, Inc.
Via
AccessWire
Could This Company's Gastrointestinal Drug Be A Powerful Pill For People And Animals With Chronic, Debilitating Diarrhea?
June 27, 2022
San Francisco-based Jaguar Health, Inc. (NASDAQ: JAGX), a commercial-stage pharmaceuticals company, says it is focused on developing novel, plant-based, non-opioid and sustainably derived prescription...
Via
Benzinga
Jaguar Health Announces Online Availability of a Presentation on Short Bowel Syndrome (SBS) by Dr. Mohamad Miqdady at Elite Ped-GI Congress in Abu Dhabi
June 22, 2022
SAN FRANCISCO, CA / ACCESSWIRE / June 22, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that a presentation by Dr. Mohamad Miqdady on short bowel syndrome (SBS) at the Elite Ped-GI Congress,...
From
Jaguar Health, Inc.
Via
AccessWire
67 Biggest Movers From Yesterday
June 22, 2022
Gainers Convey Health Solutions Holdings, Inc. (NYSE: CNVY) shares jumped 138.4% to close at $10.30 as the company agreed to be taken private by TPG Capital.
Via
Benzinga
45 Stocks Moving In Tuesday's Mid-Day Session
June 21, 2022
Gainers Convey Health Solutions Holdings, Inc. (NYSE: CNVY) shares jumped 138.8% to $10.31 as the company agreed to be taken private by TPG Capital,.
Via
Benzinga
Jaguar Animal Health Exhibiting at the June 23-25 American College of Veterinary Internal Medicine (ACVIM) Forum as Part of Ongoing Commercial Launch Activities for Canalevia-CA1
June 21, 2022
Canalevia®-CA1, which received conditional approval from the FDA on December 21, 2021, is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.